

Painful Bladder Syndrome/Interstitial Cystitis Successful Treatment with Montelukast: A Case Report and Literature Review

Muhammad Wajih Ullah ¹, Sunita Lakhani ², Sunder Sham ³, Afshan Rehman ⁴, Wardah Siddiq ⁵, Tariq Siddiqui ⁶

1. Cardiology, Mayo Clinic, Rochester, USA 2. Internal Medicine, Liaquat University of Medical and Health Sciences Hospital, Jamshoro, PAK 3. Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK 4. Internal Medicine, Baylor Saint Luke's Medical Center, Houston, USA 5. Internal Medicine, Beth Israel Deaconess Medical Center/Harvard Medical College, Boston, USA 6. Internal Medicine, Maharashtra Institute of Medical Education & Research, Talegaon, IND

Corresponding author: Muhammad Wajih Ullah, m.wajihullah@gmail.com

Abstract

Painful bladder syndrome/interstitial cystitis (PBS/IC) is a chronic condition characterized by pelvic pain, urinary frequency, and urgency for more than six months in the absence of urinary tract infections. The etiology of PBS/IC is still an enigma. PBS/IC is challenging for doctors to diagnose because its symptoms overlap with other diseases such as urinary tract infection, overactive bladder, or endometriosis. Hence, it is diagnosed after excluding those diseases. The prognosis of PBS/IC may vary because of multiple treatment options. In this study, we are documenting a 26-year-old female patient who was successfully treated with montelukast after diagnosed with PBS/IC.

Categories: Internal Medicine, Urology, Pulmonology

Keywords: bladder pain syndrome, montelukast, asthma

Introduction

Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disease of unknown etiology. The male-to-female ratio is 1:9 in the US population survey [1]. The International Continence Society (ICS) has defined PBS as "the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and nighttime frequency, in the absence of proven urinary infection or other obvious pathology." The ICS uses the term interstitial cystitis for the symptom syndrome associated with typical cystoscopic and histological features [2]. PBS/IC is a diagnosis of exclusion and careful assessment of its symptoms, physical examination, urinalysis, urine culture, pelvic ultrasound, and cystoscopy with biopsy are indicated to differentiate PBS/IC from other causes of these symptoms.

Conservative treatments such as patient education, non-prescription medications, and pelvic floor exercises are considered for the management of PBS/IC. Although several oral treatment strategies for PBS/IC are being studied, their efficacy is questionable. The answer to effective treatment for PBS/IC needs to come from well-designed and accurate studies. In this study, we are reporting a patient presenting with PBS/IC successfully treated with montelukast.

Case Presentation

A 26-year-old patient presented to the clinic complaining of lower belly pain and increased urinary frequency for seven months. Her daytime urinary frequency ranged from 20 to 35 times with nocturia about six to eight times. The patient's suprapubic pain was 6/10 in intensity and fluctuated quite markedly. She experienced no associated symptoms such as fever, weight/appetite changes, bowel habits, or any antecedent infection. The patient's past medical history revealed she was a diagnosed asthmatic for the past 12 years and was on low dose inhaled corticosteroids. Her past surgical and family history was unremarkable, and she had no modifiable or non-modifiable risk factors. She had a mild allergic reaction to peanuts during her childhood. She never smoked cigarettes or used any illicit drugs. Obstetrics and gynecology history revealed she was gravida 0, her last menstrual period was two weeks ago, and she had no vaginal discharge. She was in a monogamous relationship with her boyfriend for four years and she experienced mild pelvic pain during sexual intercourse. Systemic examination was unexceptional except for suprapubic tenderness.

The patient was asked to follow-up with her urine and blood tests. Her urinalysis and urine culture were insignificant. Laboratory investigations including complete blood count, fasting blood glucose, Hemoglobin A1c, erythrocyte sedimentation rate (ESR), thyroid function tests, liver function tests were within normal limits. The patient was admitted to the hospital for additional investigations. Pelvic ultrasound and cystoscopy were insignificant. Common etiologies, which could lead to an increase in urinary frequency,

Received 06/18/2018
Review began 06/21/2018
Review ended 06/21/2018
Published 06/25/2018

© Copyright 2018

Wajih Ullah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Wajih Ullah M, Lakhani S, Sham S, et al. (June 25, 2018) Painful Bladder Syndrome/Interstitial Cystitis Successful Treatment with Montelukast: A Case Report and Literature Review. Cureus 10(6): e2876. DOI 10.7759/cureus.2876

urgency, or nocturia, are urinary tract infection, overactive bladder, and endometriosis which were excluded and the patient was diagnosed with PBS/IC. During her stay in the hospital, she experienced shortness of breath secondary to asthma exacerbation. The patient was managed by inhaled beta-2 agonists, anticholinergics, and oral corticosteroids. She was also given montelukast sodium (10 mg/d), and the patient reported a drastic improvement in her shortness of breath. The following day the patient noticed a decrease in her urinary frequency and urgency. She was discharged from the hospital on inhaled low dose corticosteroids and montelukast.

At her follow-up visit, two months later, the patient's urinary symptoms were significantly reduced, and the suprapubic pain was gone.

Discussion

PBS/IC is a term used by ICS to refer to a chronic symptom complex of the bladder characterized by lower pelvic pain, urinary frequency, and urgency for more than six months in the absence of urinary tract infections [3-4]. PBS/IC is more prevalent in females and is associated with various comorbidities such as allergies, fibromyalgia, endometriosis, and pain syndromes [5-9]. Therefore, a comprehensive history and a thorough physical examination are critical and should help to differentiate PBS/IC from other conditions that may present similarly, such as urinary tract infections, overactive bladder, endometriosis, and vaginal candidiasis (Figure 1) [10].




FIGURE 1: Differential diagnosis of Painful Bladder Syndrome/Interstitial Cystitis.

PBS/IC: Painful Bladder Syndrome/Interstitial Cystitis.

Diagnosis of PBS/IC is based on the presence of classical urinary symptoms and suprapubic pain after excluding other alternative diagnoses. The investigations performed to reach a definite diagnosis are urinalysis, urine culture, pelvic ultrasound, and cystoscopy with biopsy. IC name is reserved for PBS with typical cystoscopic and histological features, whereas PBS includes pain in suprapubic or lower pelvic region. The National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) established the findings of glomerulations or Hunner's ulcers in the cystoscopy with hydrodistention as the diagnostic criteria for interstitial cystitis (IC) [11-12]. Positive biopsy findings of IC include inflammatory infiltrates and/or granulation tissue and/or detrusor mastocytosis and/or intrafascicular fibrosis [13].

The precise mechanism by which PBS/IC occurs is still unknown. However, it is believed that inflammation plays a central role in the pathogenesis of IC. One of the proposed mechanisms is the presence of leukotriene receptors in the detrusor muscle cells [14], increased urinary levels of leukotriene E4 in patients with PBS/IC and detrusor mastocytosis, suggesting a role of these proinflammatory mediators in IC [15]. Leukotriene E4 plays a role in the activation of mast cells and eosinophils. Once the mast cells are activated, they release vasoactive, inflammatory and nociceptive mediators, including kinin, leukotrienes, protease,

prostaglandins, and nitric oxide [16-17], which are of utmost importance in chronic inflammatory disorders. Many symptoms and findings of IC such as pain, urinary frequency, edema, and fibrosis can be explained by mast cell-derived mediators. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, has an anti-inflammatory role by inhibiting leukotriene receptors present in the bladder, thus, preventing the activation of mast cells.

Our patient was diagnosed with PBS/IC and during her stay in the hospital, she had an exacerbation of her asthma. After stabilizing her, the patient was discharged with corticosteroids and montelukast. At her two months follow-up visit, the patient reported significant improvement in her urinary symptoms and suprapubic pain. We believe that montelukast is an effective treatment option for PBS/IC patients due to its anti-inflammatory effect by inhibiting recruitment of mast cells and eosinophils (Figure 2).




FIGURE 2: Leukotriene metabolites and their actions.

Similar results were observed by Bouchelouche et al. in a pilot study. Ten women with IC (diagnosed according to the NIDDK criteria and who also had detrusor mastocytosis with a minimum of 28 mast cells per mm) received 10 mg of montelukast daily for three months. After three months of montelukast treatment, there was a statistically significant decrease in the 24-hour urinary frequency, nocturia, and pain [18].

Conclusions

PBS/IC is a not well-defined condition and its prevalence is increasing, especially among women. It is diagnosed clinically after excluding diseases which may present in an analogous way. The diagnosis is challenging and fewer effective treatments exist. In the context of this case study, the patient diagnosed with PBS/IC was successfully treated with montelukast, which may serve as a clue to support its role in PBS/IC treatment especially in patients with a history of allergic asthma.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Jones CA, Nyberg L: Epidemiology of interstitial cystitis. *Urology*. 1997, 49:2-9.
2. Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology*. 2003, 61:37-49. [10.1016/S0090-4295\(02\)02243-4](https://doi.org/10.1016/S0090-4295(02)02243-4)
3. Buffington CA: Comorbidity of interstitial cystitis with other unexplained clinical conditions. *J Urol*. 2004, 172:1242-1248. [10.1097/01.ju.0000137953.49304.6c](https://doi.org/10.1097/01.ju.0000137953.49304.6c)
4. Hanno PM: Interstitial cystitis and related disorders. *Campbell's Urology*. Walsh PC, Wein AJ, Retik AB (ed): Elsevier, Philadelphia; 2002. 631-668.
5. Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H: Interstitial cystitis costs, treatment and comorbidities in an employed population. *Pharmacoeconomics*. 2006, 24:55-65.
6. Theoharides TC, Pang X, Letourneau R, Sant GR: Interstitial cystitis: a neuroimmunoenocrine disorder. *Ann N Y Acad Sci*. 1998, 840:619-634. [10.1111/j.1749-6632.1998.tb09601.x](https://doi.org/10.1111/j.1749-6632.1998.tb09601.x)
7. Kozioł JA, Clark DC, Gittes RF, Tan EM: The natural history of interstitial cystitis: a survey of 374 patients. *J Urol*. 1993, 149:465-469. [10.1016/S0022-5347\(17\)36120-7](https://doi.org/10.1016/S0022-5347(17)36120-7)
8. Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM: Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology*. 1997, 49:52-57. [10.1016/S0090-4295\(99\)80332-X](https://doi.org/10.1016/S0090-4295(99)80332-X)
9. Erickson DR, Morgan KC, Ordille S, Keay SK, Xie SX: Nonbladder related symptoms in patients with interstitial cystitis. *J Urol*. 2001, 166:557-562. [10.1016/S0022-5347\(05\)65984-8](https://doi.org/10.1016/S0022-5347(05)65984-8)
10. Irwin P, Samsudin A: Reinvestigation of patients with a diagnosis of interstitial cystitis: common things are sometimes common. *J Urol*. 2005, 174:584-587. [10.1097/01.ju.0000165157.09277.44](https://doi.org/10.1097/01.ju.0000165157.09277.44)
11. Wein AJ, Hanno PM, Gillenwater JY: Interstitial cystitis: an introduction to the problem. *Interstitial Cystitis*. Hanno PM, Staskin DR, Krane RJ, Wein AJ (ed): Springer, London; 1990. 3-15. [10.1007/978-1-4471-3293-6_1](https://doi.org/10.1007/978-1-4471-3293-6_1)
12. Ens G, Garrido GL: Role of cystoscopy and hydrodistention in the diagnosis of interstitial cystitis/bladder pain syndrome. *Transl Androl Urol*. 2015, 4:624-628. [10.3978%2Fj.issn.2223-4683.2015.09.04](https://doi.org/10.3978%2Fj.issn.2223-4683.2015.09.04)
13. van de Merwe JP, Nordling J, Bouchelouche P, et al.: Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. *Eur Urol*. 2008, 53:60-67. [10.1016/j.eururo.2007.09.019](https://doi.org/10.1016/j.eururo.2007.09.019)
14. Bouchelouche K, Horn T, Nordling J, Larsen S, Hald T: The action of cysteinyl-leukotrienes on intracellular calcium mobilization in human detrusor myocytes. *BJU Int*. 2001, 87:690-696. [10.1046/j.1464-410x.2001.02135.x](https://doi.org/10.1046/j.1464-410x.2001.02135.x)
15. Bouchelouche K, Kristensen B, Nordling J, Horn T, Larsen S, Hald T, Bouchelouche P: Increased urinary excretion of leukotriene E4 in patients with interstitial cystitis. *Urology*. 2001, 57:128. [10.1016/S0090-4295\(01\)01097-4](https://doi.org/10.1016/S0090-4295(01)01097-4)
16. Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol*. 2004, 146:1-12. [10.1016/j.jneuroim.2003.10.041](https://doi.org/10.1016/j.jneuroim.2003.10.041)
17. Serafin WE, Austen KF: Mediators of immediate hypersensitivity reactions. *N Engl J Med*. 1987, 317:30-34. [10.1056/NEJM198707023170106](https://doi.org/10.1056/NEJM198707023170106)
18. Bouchelouche K, Nordling J, Hald T, Bouchelouche P: The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. *J Urol*. 2001, 166:1734-1737. [10.1016/S0022-5347\(05\)65663-7](https://doi.org/10.1016/S0022-5347(05)65663-7)